Drug Profile
Galantamine transdermal - NAL Pharma
Alternative Names: NAL 8801Latest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator NAL Pharma
- Class Alkaloids; Benzazepines; Nootropics; Small molecules
- Mechanism of Action Acetylcholinesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 28 Oct 2019 No recent reports of development identified for clinical-Phase-Unknown development in Alzheimer's-disease in Unknown (Transdermal, Patch)
- 01 Sep 2016 Chemical structure information added
- 12 Aug 2016 Galantamine transdermal - NAL Pharma is available for licensing as of 12 Aug 2016. http://www.nalpharma.com/licensing.php?id=6&lang=en